Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Glycemic and Psychosocial Outcomes of Advanced Hybrid Closed-Loop Therapy in Youth With High HbA1c: A Randomized Clinical Trial

To determine the efficacy of advanced hybrid closed-loop therapy in a high-risk cohort of youth on continuous subcutaneous insulin infusion with or without continuous glucose monitoring with suboptimal glycemia.

Research

Impact of Parent-Reported Antibiotic Allergies on Pediatric Antimicrobial Stewardship Programs

Antimicrobial stewardship (AMS) is crucial for optimizing antimicrobial use and restraining emergence of antimicrobial resistance. The overall increase in reported antibiotic allergies in children can pose a significant barrier to AMS, but its impact on clinical AMS care in children has not been addressed.

Research

Spatial co-distribution of tuberculosis prevalence and low BCG vaccination coverage in Ethiopia

While bacille-calmette-guerin (BCG) vaccination is one of the recommended strategies for preventing tuberculosis, its coverage is low in several countries, including Ethiopia. This study investigated the spatial co-distribution and drivers of TB prevalence and low BCG coverage in Ethiopia.

Research

Developmental queer and trans actualizations: A clear pathway to promoting health and well-being for sexually and gender diverse youth

Minority stress models and trauma-focused approaches have predominated our understanding and responses to health disparities among sexually and gender diverse (SGD) young people for more than 30 years. While the impacts and root causes of adversities are undoubtedly critical for promoting SGD health and well-being, it is important to highlight strengths-based narratives of the lives of SGD youth.

Research

Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case series

Ensitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited.

Research

Corrigendum to “A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared

Peter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group

SToP-ping skin sores in the Kimberley

More than 3,000 skin checks have been undertaken as part of a large clinical trial in WA’s Kimberley region aimed at halving the burden of skin sores in school-aged Aboriginal children.

New roadmap to help families navigate support for autistic children

Australia’s first national guideline for supporting the learning, participation and wellbeing of autistic children and their families.

Researchers make progress on 'superhero' phage therapy

Cystic fibrosis (CF) researchers are working hard to progress phage therapy as an alternative treatment to antibiotics in people with CF who develop life-threatening lung infections.

Pneumococcal vaccine sees hospital admissions for deadly pneumonia slashed

New research has revealed the extraordinary impact of a collaborative project between The Kids Research Institute Australia and the Papua New Guinea Institute of Medical Research, with rates of hospitalisation for pneumonia dropping by nearly 60 per cent thanks to the introduction of the pneumococcal vaccine